Although these differences did not quite reach statistical significance due to the small numbers, they suggest that docetaxel resistance is twice as likely in TMPRSS2 ERG-positive CRPC than in TMPRSS2 ERG-negative prostate cancers.
1
—
—
Although these differences did not quite reach statistical significance due to the small numbers, they suggest that docetaxel resistance is twice as likely in TMPRSS2 ERG-positive CRPC than in TMPRSS2 ERG-negative prostate cancers.